生物
trk受体
从长凳到床边
小分子
激酶
计算生物学
癌症研究
下载
生物信息学
遗传学
受体
万维网
计算机科学
医学物理学
神经营养素
物理
作者
Franklin W. Huang,Felix Y. Feng
出处
期刊:Cell
[Cell Press]
日期:2019-03-01
卷期号:177 (1): 8-8
被引量:48
标识
DOI:10.1016/j.cell.2019.02.049
摘要
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
科研通智能强力驱动
Strongly Powered by AbleSci AI